# Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

> **NCT03456843** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yale University** · enrollment: 190 (estimated)

## Conditions studied

- Stage IV Prostate Adenocarcinoma AJCC v7

## Interventions

- **DRUG:** Antiandrogen Therapy
- **DRUG:** Docetaxel
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Radical Prostatectomy

## Key facts

- **NCT ID:** NCT03456843
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-03-20
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03456843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03456843, "Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-18 from https://api.ai-analytics.org/clinical/NCT03456843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*